L-Carnitine (Injectable)

Unverified protocol notes

Protocol logic check

Independent evidence

Regulatory status: approved drug label available for levocarnitine injection

Storage

Store vials at controlled room temperature 25 C; avoid excessive heat; protect from freezing; discard unused portion because no preservative is present.

Contraindications (limited evidence)

• Hypothyroidism (may interfere with thyroid hormone action): L-Carnitine acts as a functional thyroid hormone antagonist at the receptor level; it inhibits thyroid hormone entry into cell nuclei, reducing gene transactivation by T3 and T4; subjects with hypothyroidism should be aware that L-Carnitine supplementation may worsen hypothyroid symptoms or reduce the effectiveness of levothyroxine therapy. Limited / unverified
• Concurrent levothyroxine or thyroid hormone therapy: L-Carnitine's peripheral anti-thyroid action may reduce the effectiveness of thyroid replacement therapy; monitor thyroid function if co-administering. Limited / unverified
• End-stage renal disease (ESRD) without dialysis: L-Carnitine is renally excreted; accumulation to toxic levels is possible in severe renal failure; patients on hemodialysis may actually require carnitine supplementation due to dialytic losses, but administration should be clinically supervised. Limited / unverified
• Seizure disorder: rare reports of increased seizure frequency in subjects with pre-existing seizure disorders using L-Carnitine supplementation; mechanism not fully characterized; use with caution. Limited / unverified
• Known hypersensitivity to L-Carnitine or injectable formulation excipients. Limited / unverified
• Concurrent anticoagulant therapy (warfarin): case reports suggest L-Carnitine potentiates the anticoagulant effect of warfarin; INR monitoring is warranted if co-administering. Limited / unverified
• Trimethylaminuria (fish odor syndrome): subjects with impaired FMO3 enzyme activity cannot efficiently oxidize TMA to TMAO; even injectable carnitine metabolism may produce systemic TMA accumulation and severe body odor. Limited / unverified

Side effects (limited evidence)

• Fishy body odor (trimethylaminuria-like effect): the most characteristically reported adverse effect at higher injectable doses; occurs as L-Carnitine metabolism produces trimethylamine as a byproduct; some individuals are poor metabolizers of TMA to TMAO; the odor can be significant and socially notable; injectable routes reduce but do not eliminate this risk compared to oral. Limited / unverified
• Injection site pain and local reactions: injectable L-Carnitine solutions are often hyperosmolar; subcutaneous administration can cause burning, stinging, and localized irritation; IM injection is sometimes preferred for volume and tolerability reasons. Limited / unverified
• Nausea and gastrointestinal discomfort: more common with oral forms but reported with high-dose injectable use. Limited / unverified
• Diarrhea: at high doses; related to systemic carnitine load. Limited / unverified
• Headache: mild; occasional; mechanism not characterized. Limited / unverified
• Restlessness or mild insomnia: reported in sensitive individuals at higher doses; carnitine's role in mitochondrial activation may have a mild stimulatory quality in some subjects. Limited / unverified
• Hypothyroidism worsening: functional anti-thyroid effect in subjects with compromised thyroid function; thyroid-sensitive subjects should monitor thyroid panel. Limited / unverified
• Elevated TMAO (trimethylamine N-oxide): cardiovascular risk concern at chronic high doses; the injectable route mitigates but does not entirely eliminate TMAO production; relevance at standard research protocol doses is uncertain. Limited / unverified
• Muscle weakness in subjects with carnitine-related metabolic disorders: paradoxical; subjects with organic acidemias or other disorders of carnitine metabolism may experience unusual responses to supplementation. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were Carnitor label states compatibility/stability in 0.9% sodium chloride or lactated Ringer's at specified concentrations for up to 24 hours at room temperature. independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

None listed.

Reported contraindicated combinations:

None listed.

Sources

• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf801cc4-775e-433d-9d32-e5d9a98981d3